Bayer terminated a two-year-old partnership with Atara Biotherapeutics that included the development of off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.

Two life sciences powerhouses are coming together to develop an off-the-shelf beta cell replacement therapy for insulin-dependent diabetes patients, which they hope will become a functional cure for both types of the disease.

Leading life sciences venture firm Sofinnova Partners entered into a long-term strategic and financial partnership with Apollo, a high-growth, alternative asset manager looking to expand its presence in the life sciences.

Lasso, the world’s first and only omnichannel platform for healthcare marketing and analytics, announced the launch of its new endemic Publisher Suite to continue Lasso’s mission of becoming a true end-to-end operating system.

Amphista Therapeutics forged two significant protein degradation partnerships with big pharma. On May 4, the U.K.-based company announced partnerships with both Bristol Myers Squibb and Merck KGaA that have a combined value of more than $2 billion.

EVERSANA, the pioneer of next-generation commercial services to the global life sciences industry, and Vector Pharma FZCO of Dubai UAE, the leading full-service distributor for rare disease, oncology and highly specialized therapeutics in the Middle East, North Africa and Turkish markets, announced a strategic partnership to expand services across the Middle East and North African markets.

AbbVie

AbbVie terminated the company’s collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement disorders.

Regeneron is acquiring Checkmate Pharmaceuticals and entered a clinical trial collaboration with SpringWorks Therapeutics to evaluate REGN5458 in multiple myeloma in combination with nirogacestat.

Bristol Myers Squibb

Nektar Therapeutics said on April 14 the company had stopped all clinical trials involving the drug developer’s key cancer drug bempegaldesleukin following its failure in multiple studies, dragging Nektar shares down 23% in after-market trading.

EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, and UpScriptHealth, a leading telehealth and virtual prescribing platform serving life sciences companies, announced a strategic partnership to create a direct-to-patient platform that will transform the patient experience to help accelerate access to therapies worldwide.